Latest News

Blue Note Explores the Impact of Technology on Cancer Care at the NCCN Virtual Policy Summit

November 2021

In September, Blue Note presented at the National Comprehensive Cancer Network's Virtual Policy Summit to discuss how new technologies, like prescription digital therapeutics, are transforming cancer care.

Read more →

Blue Note Therapeutics Announces New Collaboration for its Prescription Digital Therapeutic Candidate

September 2021

Blue Note Therapeutics enters a new collaboration under Memorial Sloan Kettering Cancer Center's Innovation Hub to help advance the company's PDT and increase capacity to reach patients.

Read more →

Blue Note Therapeutics Raises $5.2M in Additional Series A Funding

September 2021

Company raises additional Series A financing strengthening capacity to develop evidence-based therapeutics that serve an increasing number of cancer patients.

Read more →

Durham VA Health Care System and Blue Note Therapeutics Commence Phase 2 Study of First-of-its-Kind Prescription Digital Therapeutic to Address Cancer-Related Distress in Veterans

August 2021

Blue Note has partnered with Durham VA Health Care System to address cancer-related distress in veterans where there is an immediate opportunity to improve and expand access to quality mental health care.

Read more →

Blue Note Therapeutics Announces Recruitment for Registrational Clinical Trial Studying Effectiveness of Digital Medical Devices in Cancer Patients

June 2021

Blue Note announces recruitment for a clinical trial of two medical devices for improving mental and physical health.

Read more →

Blue Note Therapeutics and University of California Los Angeles Jonsson Comprehensive Cancer Center Commence a Single-Arm Open-Label Phase 2 Study for BNT001

May 2021

Blue Note partners with UCLA as company's first PDT candidate enters Phase 2 clinical trials.

Read more →

Blue Note Therapeutics Raises $26.25 Million in Series A Financing

March 2021

Company announces closing of Series A financing to scale the organization and support lead candidate, BNT001.

Read more →

Blue Note Therapeutics Partnering with Patient Advocacy Groups to Provide Digital Cancer-Related Mental Health Care During Pandemic

January 2021

Blue Note Therapeutics' 2020 year-end wrap-up.

Read more →

Blue Note Therapeutics Enters Licensing Agreement with Massachusetts General Hospital for Digital Therapeutic for Acute Myeloid Leukemia Patients

October 2020

Blue Note prepares to advance development of online mental health treatment for those with AML.

Read more →

Blue Note Therapeutics Enters Agreement to Create a Prescription Digital Therapeutic Medical Device for Cancer Patients

September 2020

Memorial Sloan Kettering Cancer Center (MSK) and Blue Note Therapeutics, Inc. have agreed to collaborate on creating a prescription digital therapeutic medical device from a psychological intervention created specifically for cancer patients with advanced cancer.

Read more →